Study of XB010 in Subjects With Solid Tumors

Summary

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Locally Advanced or Metastatic Solid Tumors
• Esophageal Squamous Cell Cancer
• Head and Neck Squamous Cell Cancer
• NSCLC (Non-small Cell Lung Cancer)
• Hormone-receptor-positive Breast Cancer
• Triple Negative Breast Cancer (TNBC)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Exelixis

Last updated on ClinicalTrials.gov

October 15, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites